Recommendations for the Reporting of Pleural Mesothelioma
|
|
- Adrian McKenzie
- 8 years ago
- Views:
Transcription
1 Recommendations for the Reporting of Pleural Mesothelioma Association of Directors of Anatomic and Surgical Pathology * DOI: /6A30YQHBMTHEJTEM It has been evident for decades that pathology reports are very variable even within a single institution. Standardization of reporting is the optimal way to ensure that information necessary for patient management, prognostic and predictive factor assessment, grading, staging, analysis of outcomes, and tumor registries is included in pathology reports. In recent years, 2 societies (first the Association of Directors of Anatomic and Surgical Pathology [ADASP] and then the College of American Pathologists [CAP]) have undertaken the publishing of guidelines for the reporting of common cancers. The CAP assigned multidisciplinary groups of pathologists, surgeons, and radiation and medical oncologists to develop the protocols. Other pathologists and clinicians then reviewed them. After the reviews, the protocols were reviewed by multiple CAP committees and finally approved by its Board of Governors. The ADASP, in contrast, chose a pathologist expert in each field to assemble a group from within the pathology community (with clinician input if desired) to write specific cancer protocols. These were then approved by the ADASP council and subsequently by the membership. Even though both societies began the process at approximately the same time, the streamlined approach adopted by the ADASP enabled it to publish years earlier in pathology journals frequented by anatomic pathologists. Although the formats are somewhat different, the contents are essentially the same. The American College of Surgeons Commission on Cancer (COC) accredits cancer centers in the United States. Recently, the COC decided to require elements deemed as essential by the CAP to be described in all pathology reports in accredited cancer centers as of January It is important to note that it does not require that the specific CAP protocols or synoptic reports be used. ADASP has updated all of its protocols to comply with the COC requirements in the form of 37 uniform checklists. The checklists use the staging criteria cited in the American Joint Committee on Cancer 2002 staging manual (sixth edition) but include a variety of other references listed in each of the checklists. Moreover, the checklists are formatted for ease of use. They may be used as templates for uniform reporting and are designed to be compatible with voice-activated transcription. The different elements in these revised ADASP diagnostic checklists have been divided into required and optional. The term required in this context only signifies compliance with the COC guidelines. ADASP realizes that specimens and practices vary and that it will not be possible to report these elements in every case. However, ADASP hopes that pathologists will find these checklists useful in daily clinical practice, while facilitating compliance with the new COC requirements. The checklists are in standard PDF file format and may be easily downloaded from the ADASP Web site. They are not to be reproduced, altered, or used for commercial purposes without consent from ADASP. Features Required to Be Included in the Final Report The following features are required by ADASP to be included in the final report because they are generally accepted as being of prognostic importance, required for therapy, and/or traditionally expected. These guidelines are primarily intended for extrapleural pneumonectomy specimens, but may also be used to report features in less extensive resection and biopsy specimens as appropriate. 1-4 Am J Clin Pathol 2007;127: DOI: /6A30YQHBMTHEJTEM 15
2 ADASP / REPORTING PLEURAL MESOTHELIOMA I. Gross description A. How the specimen was received unfixed or in formalin, intact or disrupted, oriented or not B. How the specimen was identified and procedure labeled (with, eg, patient s name, medical record number, surgical pathology accession number), designated as pleura (and other organs, as applicable), laterality, and procedure (core needle biopsy, thoracoscopic biopsy, thoracotomy and incisional biopsy, pleurectomy, or extrapleural pneumonectomy) C. Size and tissue(s) included overall size of the specimen should be measured in 3 dimensions and the tissues included in the specimen (eg, pleura, chest wall adipose tissue and/or skeletal muscle, rib[s], diaphragm, lymph nodes, mediastinal structures) documented D. Tumor description 1. Distribution diffuse, nodular, localized/solitary 2. Extent of pleura involved (circumferential, subtotal) and presence or absence of involvement of fissures and interlobular septa 3. Document dominant tumor mass(es) and size 4. Appearance color(s), texture (eg, firm, soft, gritty), infiltrative 5. Distance to closest resection margins (lateral soft tissue [chest wall] margin, bronchus, pulmonary vessels, mediastinal structures [if included], diaphragm) 6. Document appearance of excised thoracoscopic sites, if applicable (usually submitted separately) NOTE: Closest resection margins should be inked and sampled using perpendicular sections for areas where there is gross suspicion of involvement. 7. Involvement of adjacent tissues (eg, diaphragm, pericardium, lung, ribs, chest wall adipose tissue or skeletal muscle) 8. Lymph nodes number received (if any), site of origin, size, and description of cut surface 9. Specify location or orientation of each tissue block taken for routine processing 10. Description of the nonneoplastic pleura, lung, and other tissues 11. Whether a diagnostic frozen section was performed and the intraoperative diagnosis II. Diagnostic information A. Site, laterality, and procedure B. Histologic type 5 1. Epithelioid 2. Sarcomatoid 3. Biphasic 4. Desmoplastic 5. Other (specify) C. Extent of invasion document involvement of parietal and visceral pleura, diaphragm, lung, endothoracic fascia, mediastinal adipose tissue and/or organs, chest wall soft tissue (solitary or diffuse involvement), rib(s) D. Resection margin status positive (state which margin) or negative E. Lymph node status (if present) specific site(s) and number involved out of total for each site F. Pathologic stage based on pathologic features as reported above Features Optional for the Final Report Features in the following list may impact on the likelihood of recurrence or overall prognosis. They represent specific institutional preferences, or they are considered inconclusive vis-à-vis prognostic significance. Lymphovascular invasion Blood vessel invasion Findings in the nonneoplastic pleura and lung (eg, changes consistent with prior talc pleurodesis, plaques, fibrosis, asbestos bodies, asbestosis) NOTE: Owing to the etiologic association between asbestos exposure and malignant mesothelioma, quantitative fiber burden analysis may be requested in cases that include lung tissue as part of the specimen. Formalin-fixed, nonneoplastic lung tissue (at least 5 g), preferably from the lower lobe, may be stored for this purpose. Results of any ancillary studies (eg, histochemical stains, immunohistochemical analysis, electron microscopy) NOTE: Given the cytomorphologic overlap between malignant epithelioid mesothelioma and metastatic adenocarcinoma or malignant sarcomatoid mesothelioma and primary or metastatic sarcomas, ancillary techniques (eg, immunohistochemical analysis and/or electron microscopy) are routinely used to facilitate diagnosis. Because no single immunohistochemical marker is entirely sensitive or specific for malignant mesothelioma, a panel of stains should be used. The ADASP does not prescribe a particular panel of markers but recommends that at least 2 mesothelialassociated markers (eg, calretinin, cytokeratins 5/6, D2-40, WT1) be used in conjunction with 2 or more markers that are usually negative in malignant mesothelioma (eg, carcinoembryonic antigen, thyroid transcription factor-1, Ber- EP4, MOC-31) The results of ancillary techniques should be carefully correlated with the radiographic and gross distribution of tumor. * Committee members are Kelly J. Butnor, MD 1 (chairperson); Thomas A. Sporn, MD, 2 and Nelson G. Ordonez, MD, 3 from the Departments of Pathology, 1 University of Vermont, Burlington; 2 Duke University, Durham, NC; and 3 M.D. Anderson Cancer Center, Houston, TX. 16 Am J Clin Pathol 2007;127: DOI: /6A30YQHBMTHEJTEM
3 References 1. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma: from the International Mesothelioma Interest Group. Chest. 1995;108: Rusch VW, Venkatraman ES. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann Thorac Surg. 1999;68: Sugarbaker DJ, Garcia JP, Richards WG, et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma: results in 120 consecutive patients. Ann Surg. 1996;224: Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg. 1999;117: Churg A, Roggli VL, Galateau-Salle F, et al. Mesothelioma. In: Travis WD, Brambilla E, Muller-Hermelink HK, et al, eds. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus, and Heart. Lyon, France: IARC Press; 2004: World Health Organization Classification of Tumours. 6. Chu AY, Litzky LA, Pasha TL, et al. Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol. 2005;18: Cury PM, Butcher DN, Fisher C, et al. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol. 2000;13: Di Loreto C, Puglisi F, Di Lauro V, et al. TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung. Cancer Lett. 1998;124: Ordonez NG. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol. 1998;22: Ordonez NG. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma: the M.D. Anderson experience and a critical review of the literature. Am J Clin Pathol. 1998;109: Association of Directors of Anatomic and Surgical Pathology (Ver ) Final Anatomic Diagnosis Checklist Pleural Mesothelioma Accession No.: Part No.: Date: Patient Name: Organ Site Operation Parietal pleura Right Core needle biopsy * Left Thoracoscopic biopsy * Visceral pleura Diaphragmatic Thoracotomy and incisional biopsy * Pleurectomy * Extrapleural pneumonectomy Other: * This checklist is primarily for extrapleural pneumonectomy specimens. For less extensive resection/biopsy specimens, not all of the checklist elements will apply. Primary Tumor Diagnosis (Required) Epithelioid (epithelial) mesothelioma Sarcomatoid mesothelioma Biphasic mesothelioma Desmoplastic mesothelioma Other: Am J Clin Pathol 2007;127: DOI: /6A30YQHBMTHEJTEM 17
4 ADASP / REPORTING PLEURAL MESOTHELIOMA I. Extent of tumor (Required) A. Tumor involves parietal pleura with/without involvement of the ipsilateral visceral pleura B. Tumor involves ipsilateral parietal/visceral/parietal and visceral pleura with 1. Confluence of tumor involving the visceral pleura (including the fissure) 2. Invasion into but not through the diaphragm 3. Invasion of lung parenchyma 4. Invasion of the endothoracic fascia 5. Invasion into mediastinal adipose tissue 6. Solitary focus of tumor invading the soft tissue of the chest wall 7. Invasion into but not through the pericardium 8. Diffuse or multiple foci of tumor invading the soft tissue of the chest wall 9. Invasion of rib 10. Invasion through the diaphragm into the peritoneum 11. Invasion into great vessels/esophagus/trachea/other (mediastinal organ) 12. Direct extension into contralateral pleura 13. Invasion of the vertebra 14. Involvement of the inner surface of the pericardium 15. Invasion of the myocardium 16. Invasion of the brachial plexus II. Margins of excision (Required) 1. Surgical margins are free of malignant mesothelioma 2. Malignant mesothelioma is present at margin(s) of excision NOTE: All of the following lymph node groups will not be identified in most cases. However, appropriate designations are provided below. Lymph nodes (peribronchial, specify laterality): Lymph nodes (hilar, specify laterality): NOTE: Regional lymph nodes include internal mammary, intrathoracic, scalene, and supraclavicular lymph nodes. The regional lymph node mapping and staging are the same as for pulmonary carcinoma. 18 Am J Clin Pathol 2007;127: DOI: /6A30YQHBMTHEJTEM
5 Additional Tumor Features (Optional) A. Lymphatic vessel invasion: Identified Not identified B. Blood vessel invasion: Identified Not identified Nonneoplastic lung/pleura (Optional) A. Asbestos bodies identified B. Pleural plaques identified C. Interstitial fibrosis present D. Changes consistent with prior talc pleurodesis identified Comment: Ancillary Studies (Optional) Special stains are performed, the results are as follows: A. B. C. D. Interpretation Immunohistochemical studies are performed, the results are as follows: A. B. C. D. E. F. G. H. Interpretation ptn stage 1 (Required) A. Primary tumor 1. ptx Primary tumor cannot be assessed 2. pt0 No evidence of primary tumor 3. pt1a Tumor involves ipsilateral parietal (mediastinal, diaphragmatic) pleura, without involvement of the visceral pleura 4. pt1b Tumor involves ipsilateral parietal (mediastinal, diaphragmatic) pleura, with focal involvement of the visceral pleura 5. pt2 Tumor involves any of the ipsilateral pleural surfaces with at least one of the following: Confluent visceral pleural tumor (including fissure) Invasion of diaphragmatic muscle Solitary focus of tumor invading the soft tissues of the chest wall Invasion of lung parenchyma 6. pt3 Tumor involves any of the ipsilateral pleural surfaces with at least one of the following: Invasion of the endothoracic fascia Invasion intro mediastinal fat Solitary focus of tumor invading the soft tissues of the chest wall Nontransmural involvement of the pericardium 7. pt4 Tumor involves any of the ipsilateral pleural surfaces with at least one of the following: Diffuse or multifocal invasion of the soft tissues of the chest wall Any involvement of rib Invasion through the diaphragm into the peritoneum Invasion of any mediastinal organs Direct extension to the contralateral pleura Invasion into the spine Extension to the internal surface of the pericardium Pericardial effusion with positive cytology Invasion of the myocardium Invasion of the brachial plexus B. Regional lymph nodes 1. pnx Regional lymph nodes cannot be assessed 2. pn0 No regional lymph node metastasis 3. pn1 Metastasis in ipsilateral bronchopulmonary and/or hilar lymph node(s) 4. pn2 Metastasis in the subcarinal lymph node(s) and/or ipsilateral internal mammary or mediastinal lymph node(s) 5. pn3 Metastasis in contralateral mediastinal, internal mammary, or hilar lymph node(s) and/or the ipsilateral or contralateral supraclavicular or scalene lymph node(s) C. Distant metastasis 1. pmx Cannot be assessed 2. pm0 No distant metastasis 3. pm1 Distant metastasis Reference 1. Greene FL, Page BL, Fleming ID, et al (American Joint Committee on Cancer), eds. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002: Am J Clin Pathol 2007;127: DOI: /6A30YQHBMTHEJTEM 19
Protocol for the Examination of Specimens From Patients With Malignant Pleural Mesothelioma
Protocol for the Examination of Specimens From Patients With Malignant Pleural Mesothelioma Based on AJCC/UICC TNM, 7th edition Protocol web posting date: February 1, 2011 Procedures Resection Authors
More informationExtrapleural Pneumonectomy for Malignant Mesothelioma: Pro. Joon H. Lee 9/17/2012
Extrapleural Pneumonectomy for Malignant Mesothelioma: Pro Joon H. Lee 9/17/2012 Malignant Pleural Mesothelioma (Epidemiology) Incidence: 7/mil (Japan) to 40/mil (Australia) Attributed secondary to asbestos
More informationThoracic Mesothelium. Protocol applies to malignant thoracic mesothelioma. Procedures Cytology (No Accompanying Checklist) Incisional Biopsy Resection
Thoracic Mesothelium Protocol applies to malignant thoracic mesothelioma. Protocol revision date: January 2004 Based on AJCC/UICC TNM, 6 th edition Procedures Cytology (No Accompanying Checklist) Incisional
More informationObjectives. Mylene T. Truong, MD. Malignant Pleural Mesothelioma Background
Imaging of Pleural Tumors Mylene T. Truong, MD Imaging of Pleural Tumours Mylene T. Truong, M. D. University of Texas M.D. Anderson Cancer Center, Houston, TX Objectives To review tumors involving the
More informationUpdate on Mesothelioma
November 8, 2012 Update on Mesothelioma Intro incidence and nomenclature Update on Classification Diagnostic specimens Morphologic features Epithelioid Histology Biphasic Histology Immunohistochemical
More informationStandards and datasets for reporting cancers. Dataset for the histological reporting of mesothelioma. April 2013
Standards and datasets for reporting cancers Dataset for the histological reporting of mesothelioma April 2013 Authors Professor Andrew G Nicholson, Royal Brompton Hospital and Harefield NHS Trust Professor
More informationINTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project
INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER Prospective Mesothelioma Staging Project Data Forms and Fields in CRAB Electronic Data Capture System - Reduced Set - Pivotal data elements for developing
More informationMesothelioma. 1. Introduction. 1.1 General Information and Aetiology
Mesothelioma 1. Introduction 1.1 General Information and Aetiology Mesotheliomas are tumours that arise from the mesothelial cells of the pleura, peritoneum, pericardium or tunica vaginalis [1]. Most are
More informationPathology of lung cancer
Pathology of lung cancer EASO COURSE ON LUNG CANCER AND MESOTHELIOMA DAMASCUS (SYRIA), MAY 3-4, 2007 Gérard ABADJIAN MD Pathologist Associate Professor, Saint Joseph University Pathology Dept. Hôtel-Dieu
More informationMalignant Mesothelioma Current Approaches to a Difficult Problem. Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center
Malignant Mesothelioma Current Approaches to a Difficult Problem Raja M Flores, MD Thoracic Surgery Memorial Sloan-Kettering Cancer Center Malignant Pleural Mesothelioma Clinical Presentation Insidious
More informationProposed Adjustments to Pathologic Staging of Epithelial Malignant Pleural Mesothelioma Based on Analysis of 354 Cases
Original Article Proposed Adjustments to Pathologic Staging of Epithelial Malignant Pleural Mesothelioma Based on Analysis of 354 Cases William G. Richards, PhD 1,2 ; John J. Godleski, MD 2,3 ; Beow Y.
More informationDiagnosis of Mesothelioma Pitfalls and Practical Information
Diagnosis of Mesothelioma Pitfalls and Practical Information Mary Beth Beasley, M.D. Mt Sinai Medical Ctr Dept of Pathology One Gustave L Levy Place New York, NY 10029 (212) 241-5307 mbbeasleymd@yahoo.com
More informationHow To Write Lung Cancer Data Standards For Nhs Scotland
For reference only Do Not Use For more information contact: cdsis@nhs.net Lung Cancer Pathology Data Standards June 2008 National Clinical Dataset Development Programme (NCDDP) Support Team Information
More informationبسم هللا الرحمن الرحيم
بسم هللا الرحمن الرحيم Updates in Mesothelioma By Samieh Amer, MD Professor of Cardiothoracic Surgery Faculty of Medicine, Cairo University History Wagner and his colleagues (1960) 33 cases of mesothelioma
More informationThe Proposed New International TNM Staging System for Malignant Pleural Mesothelioma: Application to Imaging
323.....:. #{149} :. #{149}..: #{149}. #{149}. :- : Received June 22, 1995; accepted after revision September 12, 1995. 1 Department of Radiology, Duke University Medical Center, Box 3808, Dunham, NC 2771
More informationPrimary -Benign - Malignant Secondary
TUMOURS OF THE LUNG Primary -Benign - Malignant Secondary The incidence of lung cancer has been increasing almost logarithmically and is now reaching epidemic levels. The overall cure rate is very low
More informationAhmed Farouk Abd El-Hafez, MD
Presented By Ahmed Farouk Abd El-Hafez, MD Lecturer of Cardiothoracic Surgery Assiut University Asbestos exposure : amphibole fibers especially crocidolite asbestos Nonasbestos Causes : Silicate fibers
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES LUNG SITE MESOTHELIOMA Lung Site Group Mesothelioma Date Guideline Created: April 2013 Authors: Dr. Meredith Giuliani, Dr. Andrea Bezjak 1.
More informationSternotomy and removal of the tumor
Sternotomy and removal of the tumor All thymomas originate from epithelial thymic cells 4% of them consist of a pure population of epithelial cells Most have mixed populations of lymphoid cells to a
More informationPlueral Malignancy: Radiologic-pathologic
Plueral Malignancy: Radiologic-pathologic Correlation Ritu R. Gill, MD Pleural Malignancies: Radiologic-Pathologic Correlation Ritu R Gill MD Brigham and Women s Hospital Boston, Massachusetts Pleural
More informationCase of the. Month October, 2012
Case of the Month October, 2012 Case The patient is a 47-year-old male with a 3-week history of abdominal pain. A CT scan of the abdomen revealed a suggestion of wall thickening at the tip of the appendix
More informationTreatment of mesothelioma in Bloemfontein, South Africa
European Journal of Cardio-thoracic Surgery 24 (2003) 434 440 www.elsevier.com/locate/ejcts Treatment of mesothelioma in Bloemfontein, South Africa W.J. de Vries*, M.A. Long Cardiothoracic Department,
More informationIII II II 111111111111111111111111111111111111111111 1 1111111111111 III. ge: /ears sex: Male Access
UUID : 10F97F63 - EE6F-448D - 98E1-8AAA21F55753 TCGA - TS-A7PB-01A-PR Redacted III II II 111111111111111111111111111111111111111111 1 1111111111111 III Date Receive III 11111111111111111 11111111111 II
More informationMALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY
MALIGNANT MESOTHELIOMA CLASSIFICATION MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo,
More informationThe develpemental origin of mesothelium
Mesothelioma Tallinn 14.12.06 Henrik Wolff Finnish Institute of Occupational Health The develpemental origin of mesothelium Mesodermal cavities (pleura, peritoneum and pericardium ) are lined with mesenchymal
More informationMALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY
MALIGNANT MESOTHELIOMA UPDATE ON PATHOLOGY AND IMMUNOHISTOCHEMISTRY Sisko Anttila, MD, PhD Jorvi Hospital Laboratory of Pathology Helsinki University Hospital Espoo, Finland 2nd Nordic Conference on Applied
More informationNotice of Faculty Disclosure
The Diagnosis of Malignant Mesothelioma Andrew Churg, MD Department of Pathology University of British Columbia Vancouver, BC, Canada achurg@mail.ubc.ca Notice of Faculty Disclosure In accordance with
More informationProtocol for the Examination of Specimens From Patients With Tumors of the Peritoneum
Protocol for the Examination of Specimens From Patients With Tumors of the Peritoneum Protocol applies to all primary borderline and malignant epithelial tumors and malignant mesothelial neoplasms of the
More informationMesothelioma. Malignant Pleural Mesothelioma
Mesothelioma William G. Richards, PhD Brigham and Women s Hospital Malignant Pleural Mesothelioma 2,000-3,000 cases per year (USA) Increasing incidence Asbestos (50-80%, decreasing) 30-40 year latency
More informationOutline. Workup for metastatic breast cancer. Metastatic breast cancer
Metastatic breast cancer Immunostain Update: Diagnosis of metastatic breast carcinoma, emphasizing distinction from GYN primary 1/3 of breast cancer patients will show metastasis 1 st presentation or 20-30
More informationA 70-year old Man with Pleural Effusion
Mesothelioma Diagnosis: Pitfalls and Latest Updates S Klebe and DW Henderson Recommendations Indisputable malignant cells on cytomorphological criteria which demonstrate a mesothelial phenotype, which
More informationIASLC Mesothelioma Staging Project - Reduced Set of Data Elements for Proposals for Change to 8th Edition TNM 7/7/2013
Page 1 of 16 Patient Characteristics form (3 variables) Disease Description form (6 variables) Pre-treatment/Evaluative TNM form - Pre-Treatment/Evaluative Thickness and Effusions form - Pre-Treatment/Evaluative
More informationNeoplasms of the LUNG and PLEURA
Neoplasms of the LUNG and PLEURA 2015-2016 FCDS Educational Webcast Series Steven Peace, BS, CTR September 19, 2015 2015 Focus o Anatomy o SSS 2000 o MPH Rules o AJCC TNM 1 Case 1 Case Vignette HISTORY:
More informationMalignant Pleural Diseases Advances Clinicians Should Know F Gleeson
Malignant Pleural Diseases Advances Clinicians Should Know F Gleeson The following relevant disclosures, conflicts of interest and/ or financial relationships exist related to this presentation: Consultant
More informationPractical Effusion Cytology
Practical Effusion Cytology A Community Pathologist s Approach to Immunocytochemistry in Body Fluid Cytology Emily E. Volk, MD William Beaumont Hospital Troy, MI College of American Pathologists 2004.
More informationPleural Mesothelioma: An Institutional Experience of 66 Cases
The Korean Journal of Pathology 2014; 48: 91-99 ORIGINAL ARTICLE Pleural Mesothelioma: An Institutional Experience of 66 Cases Soomin Ahn In Ho Choi Joungho Han Jhingook Kim 1 Myung-Ju Ahn 2 Departments
More informationSeattle. Case Presentations. Case 1. 76 year old female with a history of breast cancer 12 years ago. Now presents with a pleural effusion.
Seattle Montreal IAP September 2006 Case Presentations Allen M. Gown, M.D. Medical Director and Chief Pathologist PhenoPath Laboratories Clinical Professor of Pathology University of British Columbia Case
More informationMalignant pleural mesothelioma: outcome of limited surgical management
Interactive Cardiovascular and Thoracic Surgery 2 (2003) 30 34 Institutional review Thoracic general Malignant pleural mesothelioma: outcome of limited surgical management Peter G. Phillips a, George Asimakopoulos
More informationCase based applications part III
Case based applications part III Los Angeles Society Of Pathologists January 25, 2014 Sanja Dacic, MD, PhD University of Pittsburgh Medical Center 1 CASE 1 A 44-year-old woman with multiple lung nodules.
More informationASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3
ASBESTOS EXPOSURE AND SARCOMATOID MALIGNANT PLEURAL MESOTHELIOMA Gorantla Sambasivarao 1, Namballa Usharani 2, Tupakula Suresh Babu 3 HOW TO CITE THIS ARTICLE: Gorantla Sambasivarao, Namballa Usharani,
More informationClinical Indications and Results Following Chest Wall Resection
Clinical Indications and Results Following Chest Wall Resection for Recurrent Malignant Pleural Mesothelioma Ali SO, Burt BM, Groth SS, DaSilva MC, Yeap BY, Richards WG, Baldini EH and Sugarbaker DJ. Division
More informationMalignant Mesothelioma
Malignant Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)
More informationMalignant Mesothelioma
Malignant mesothelioma is a tumour originating from mesothelial cells. 85 95% of mesotheliomas are caused by asbestos exposure. It occurs much more commonly in the chest (malignant pleural mesothelioma)
More informationAcadémie internationale de Pathologie - Division arabe XX ème congrès 24-26 novembre 2008 Alger. Immunohistochemistry in malignant mesotheliomas
Académie internationale de Pathologie - Division arabe XX ème congrès 24-26 novembre 2008 Alger Immunohistochemistry in malignant mesotheliomas Françoise Thivolet-Béjui Groupement Hospitalier Est Lyon-Bron
More informationMale. Female. Death rates from lung cancer in USA
Male Female Death rates from lung cancer in USA Smoking represents an interesting combination of an entrenched industry and a clearly drug-induced cancer Tobacco Use in the US, 1900-2000 5000 100 Per Capita
More informationYOUR LUNG CANCER PATHOLOGY REPORT
UNDERSTANDING YOUR LUNG CANCER PATHOLOGY REPORT 1-800-298-2436 LungCancerAlliance.org A GUIDE FOR THE PATIENT 1 CONTENTS What is a Pathology Report?...3 The Basics...4 Sections of a Pathology Report...7
More informationMalignant Pleural Mesothelioma in Singapore
RESEARCH COMMUNICATION C SP Yip 1, HN Koong 2, CM Loo 3, KW Fong 1* Abstract Aim: To examine the clinical characteristics and outcomes of malignant pleural mesothelioma (MPM) in Singapore. Methods and
More informationPATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry. M. Praet
PATHOLOGY OF THE PLEURA: Mesothelioma and mimickers Necessity of Immunohistochemistry M. Praet Pathology of the Pleura Normal serosa: visceral and parietal layers Inflammation Neoplasia: Primary: mesothelioma
More informationClinicopathological Study on Malignant Pleural Mesotheliomas
Table of Contents Clinicopathological Study on Malignant Pleural Mesotheliomas PL-4-03 Kenzo Hiroshima Kenzo Hiroshima 1, Akira Iyota 1, Kiyoshi Sibuya 1, Toshikazu Yusa 2, Takehiko Fujisawa 1 and Yukio
More informationProtocol applies to all primary borderline and malignant epithelial tumors, and malignant mesothelial neoplasms of the peritoneum.
Peritoneum Protocol applies to all primary borderline and malignant epithelial tumors, and malignant mesothelial neoplasms of the peritoneum. Protocol revision date: January 2004 No AJCC/UICC staging system
More informationMaterials and Methods. Results
Anatomic Pathology / Malignant Pleural Mesothelioma Histologic Assessment and Prognostic Factors of Malignant Pleural Mesothelioma Treated With Extrapleural Pneumonectomy Andrea V. Arrossi, MD, 1 E. Lin,
More informationBIOBANK LPCE-NICE CHEST
BIOBANK LE-NIE HEST athologist :. BUTORI 12/09/2013 LE / HU Unit atient : N LH13-3603 N LB 13-0691 ID : RO A onsent : YES Age : 54 Diagnosis and staging : chronic pleuresia 5x1000µL BIOBANK LE-NIE HEST
More informationThe Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin
Anatomic Pathology / TTF-1 IN CYTOLOGY OF BODY FLUIDS The Value of Thyroid Transcription Factor-1 in Cytologic Preparations as a Marker for Metastatic Adenocarcinoma of Lung Origin Jonathan L. Hecht, MD,
More informationMalignant Pleural Mesothelioma Diagnosed by Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration
http://dx.doi.org/10.4046/trd.2013.74.2.74 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2013;74:74-78 CopyrightC2013. The Korean Academy of Tuberculosis and Respiratory Diseases. All rights
More informationMESOTHELIOMA. Not Just a Late Night Commercial. Graciela Hoal, RN, MSN, ACNP-BC
MESOTHELIOMA Not Just a Late Night Commercial Graciela Hoal, RN, MSN, ACNP-BC Saturday Session Thoracic Surgery Nurse Practitioner Greater Los Angeles Veteran Affairs Objectives Course Objectives: Discuss
More informationA Practical Guide to Advances in Staging and Treatment of NSCLC
A Practical Guide to Advances in Staging and Treatment of NSCLC Robert J. Korst, M.D. Director, Thoracic Surgery Medical Director, The Blumenthal Cancer Center The Valley Hospital Objectives Revised staging
More information3-F. Pathology of Mesothelioma
3-F. Pathology of Mesothelioma Kouki Inai Professor of Department of Pathology, Graduate School of Biomedical Science, Hiroshima University Introduction Mesothelioma is a peculiar type of malignancy, which
More informationPleural and Chest Wall Tumors
Pleural and Chest Wall Tumors Ritu Gill, MD, MPH Dr. Ritu R. Gill Department t of Radiology Brigham and Women s Hospital Harvard Medical School CLASSIFICATION OF CHEST WALL TUMORS Primary neoplasm of chest
More informationRound Table with Drs. Anne Tsao and Alex Farivar, Case 2: Mesothelioma
Round Table with Drs. Anne Tsao and Alex Farivar, Case 2: Mesothelioma I d like to welcome everyone, thanks for coming out to our lunch with experts. The faculty today are great people in the thoracic
More informationResearch Article Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma
Disease Markers Volume 2015, Article ID 282145, 5 pages http://dx.doi.org/10.1155/2015/282145 Research Article Frequency of Surgery in Black Patients with Malignant Pleural Mesothelioma Emanuela Taioli,
More informationMalignant Mesothelioma
Malignant Mesothelioma What is malignant mesothelioma? Malignant mesothelioma is a cancer that starts in cells in the linings of certain parts of the body, especially in the linings of the chest or abdomen.
More informationWhat is Mesothelioma?
What is Mesothelioma? Mesothelioma is a rare type of cancer that develops in the mesothelial cells found in one s body. These cells form membranous linings that surround and protect the body s organs and
More informationUses and Abuses of Pathology in Asbestos-exposed Populations
Uses and Abuses of Pathology in Asbestos-exposed Populations Jerrold L. Abraham, MD Department of Pathology State University of New York Upstate Medical University Syracuse, NY, 13210 USA The term: Asbestosis,
More informationMalignant Mesothelioma
Malignant Mesothelioma What is malignant mesothelioma? Malignant mesothelioma is a cancer that starts in cells in the linings of certain parts of the body, especially in the linings of the chest or abdomen.
More informationIII. EXTENT OF DISEASE
Advanced Abstracting Lung Cancer III. EXTENT OF DISEASE Staging Systems and Documentation 1 Source: AJCC Cancer Staging Illustrations from the AJCC Cancer Staging Atlas. Springer, 2007. Used with permission.
More informationUnderstanding Pleural Mesothelioma
Understanding Pleural Mesothelioma UHN Information for patients and families Read this booklet to learn about: What is pleural mesothelioma? What causes it? What are the symptoms? What tests are done to
More informationMalignant Mesothelioma Diagnosed by Bronchoscopic Biopsy
CASE REPORT http://dx.doi.org/10.4046/trd.2015.78.3.297 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2015;78:297-301 Malignant Mesothelioma Diagnosed by Bronchoscopic Biopsy Yeon-Hee Park,
More informationOBJECTIVES By the end of this segment, the community participant will be able to:
Cancer 101: Cancer Diagnosis and Staging Linda U. Krebs, RN, PhD, AOCN, FAAN OCEAN Native Navigators and the Cancer Continuum (NNACC) (NCMHD R24MD002811) Cancer 101: Diagnosis & Staging (Watanabe-Galloway
More informationScreening, early referral and treatment for asbestos related cancer
Screening, early referral and treatment for asbestos related cancer Marc de Perrot, MD, MSc, FRCSC Toronto Mesothelioma Research Program University of Toronto Asbestos related diseases Mesothelioma Lung
More informationDiagnostic Challenge. Department of Pathology,
Cytology of Pleural Fluid as a Diagnostic Challenge Paavo Pääkkö,, MD, PhD Chief Physician and Head of the Department Department of Pathology, Oulu University Hospital,, Finland Oulu University Hospital
More informationDepartment of Pathology, Chiba Cancer Center, 9 Department of Thoracic Surgery, Chiba East Hospital, Chiba, 2
Pathology International 2009; 59: 537 545 doi:10.1111/j.1440-1827.2009.02404.x Original Article Malignant pleural mesothelioma: Clinicopathology of 16 extrapleural pneumonectomy patients with special reference
More informationThe New International Staging System Lung Cancer
The New International Staging System Lung Cancer Valerie W. Rusch, MD Chief, Thoracic Surgery Memorial Sloan-Kettering Cancer Center Chair, Lung and Esophagus Task Force, American Joint Commission on Cancer
More informationSystem for Malignant Pleural Mesothelioma'
A Proposed New International TNM Staging System for Malignant Pleural Mesothelioma' From the International Mesothelioma Interest Group* Study objective: Investigation of the behavior and treatment of diffuse
More informationUnderstanding Your Surgical Options for Lung Cancer
Information Booklet for Patients Understanding Your Surgical Options for Lung Cancer Understanding Lung Cancer If you have just been diagnosed with lung cancer, this booklet will serve as an informational
More informationMesothelioma: Questions and Answers
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Mesothelioma: Questions
More informationHKCPath Anatomical Pathology Peer Review and Scores : PDF version for download
AP2003R1 http://hkcpath.org. Correspondence: pkhui@ha.org.hk 1of 10 07/08/2003 HKCPath Anatomical Pathology Peer Review and Scores : PDF version for download AP141 Bone Marrow: Metastatic Carcinoma from
More informationReport series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
More informationLung cancer LUNG CANCER. Box 1 Clinical signs
22 LUNG CANCER Lung cancer Bronchial carcinoma refers to two distinct clinical entities small cell and non-small cell carcinoma. Although these conditions have much in common, with broadly similar presenting
More informationMore than 2,500 people are diagnosed with mesothelioma in the UK each year.
This information is an extract from the booklet Understanding mesothelioma. You may find the full booklet helpful. We can send you a free copy see page 5. Contents Introduction Pleural mesothelioma Peritoneal
More informationMalignant Pleural Mesothelioma. NCCN Guidelines for Patients
Malignant Pleural Mesothelioma NCCN Guidelines for Patients Presented with support from the national law firm of Baron & Budd Also available at NCCN.com About this booklet Its purpose Learning that you
More informationChanges in Breast Cancer Reports After Second Opinion. Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain
Changes in Breast Cancer Reports After Second Opinion Dr. Vicente Marco Department of Pathology Hospital Quiron Barcelona. Spain Second Opinion in Breast Pathology Usually requested when a patient is referred
More information20 Diagnostic Cytopathology, Vol 36, No 1 ' 2007 WILEY-LISS, INC.
Utility of WT-1, p63, MOC31, Mesothelin, and Cytokeratin (K903 and CK5/6) Immunostains in Differentiating Adenocarcinoma, Squamous Cell Carcinoma, and Malignant Mesothelioma in Effusions Robert T. Pu,
More informationChapter 2 Staging of Breast Cancer
Chapter 2 Staging of Breast Cancer Zeynep Ozsaran and Senem Demirci Alanyalı 2.1 Introduction Five decades ago, Denoix et al. proposed classification system (tumor node metastasis [TNM]) based on the dissemination
More informationISOLATED PANCREATIC METASTASIS OF A MALIGNANT PLEURAL MESOTHELIOMA
ISOLATED PANCREATIC METASTASIS OF A MALIGNANT PLEURAL MESOTHELIOMA Yi-Ting Lin, 1 Bing-Shiun Wu, 2 Sheau-Fang Yang, 3 and Huang-Chi Chen 4 Departments of 1 Family Medicine, 2 Internal Medicine, and 3 Pathology,
More informationContemporary Management of Malignant Pleural Mesothelioma
Contemporary Management of Malignant Pleural Mesothelioma ERIC G. BUTCHART University Hospital of Wales, Cardiff, United Kingdom Key Words. Mesothelioma Surgery Radiotherapy Chemotherapy Immunology Gene
More informationToday s Topics. Tumors of the Peritoneum in Women
Today s Topics Tumors of the Peritoneum in Women Charles Zaloudek, M.D. Department of Pathology 505 Parnassus Ave., M563 University of California, San Francisco San Francisco, CA USA charles.zaloudek@ucsf.edu
More informationThe National Clinical Lung Cancer Audit (LUCADA)
The National Clinical Lung Cancer Audit (LUCADA) DATA MANUAL Title: Version: 3.1.5 Date: September 2013 LUCADA Lung Cancer Audit VERSION HISTORY Version Date Issued Brief Summary of Change Owner s Name
More informationBIOBANK LPCE-NICE CHEST
BIOBANK LE-NIE HEST athologist : S. LASSALLE 01/03/2011 Time for frozen procedure : 10 mn LE / HU Unit atient : N LH 11-0004 N LB 11-0002 onsent : YES Age : 37 ID : TH ER Diagnosis and staging : Hodgkin
More informationINFLAMMATORY PLEURAL EFFUSION
PLEURA- LESIONS LESIONS OF PLEURA Primary Intra pleural bacterial infections Neoplasm (mesothelioma) Secondary A complication of some underlying disease PLEURAL EFFUSION Common manifestation of both primary
More informationMalignant Mesothelioma State of the Art
Malignant Mesothelioma State of the Art Paul Baas The Netherlands Cancer Institute August 12, 2011, Carlsbad, CA Summary Diagnosis; epithelial type subdivided Pleiomorphic vs other Staging: IASLC-IMIG
More informationSurgical therapy of. who should be operated
SAMO Interdisciplinary Workshop on Chest Tumors Lucerne, 13th and 14th January 2012 Surgical therapy of mesothelioma, who should be operated Walter Weder MD Professor of Surgery University Hospital Zurich
More informationB. Dingle MD, FRCPC, Brian Yaremko MD,FRCPC, R. Ash, MD, FRCPC, P. Truong, MD, FRCPC
Lung Cancer B. Dingle MD, FRCPC, Brian Yaremko MD,FRCPC, R. Ash, MD, FRCPC, P. Truong, MD, FRCPC EPIDEMIOLOGY The estimated incidence of lung cancer in Canada for 2007 is 23,300 with 12,400 occurring in
More informationHow To Treat Lung Cancer At Cleveland Clinic
Treatment Guide Lung Cancer Management The Chest Cancer Center at Cleveland Clinic, which includes specialists from the Respiratory Institute, Taussig Cancer Institute and Miller Family Heart & Vascular
More informationA Cytokeratin- and Calretinin-negative Staining Sarcomatoid Malignant Mesothelioma
A Cytokeratin- and Calretinin-negative Staining Sarcomatoid Malignant Mesothelioma MICHAEL G. HURTUK and MICHELE CARBONE Cardinal Bernadin Cancer Center, Cancer Immunology Program, Department of Pathology,
More informationFine Needle Aspiration Cytologic Features of Well-Differentiated Papillary Mesothelioma in the Pleura
The Korean Journal of Pathology 2009; 43: 583-8 DOI: 10.4132/KoreanJPathol.2009.43.6.583 Fine Needle Aspiration Cytologic Features of Well-Differentiated Papillary Mesothelioma in the Pleura - A Case Report
More informationHow To Understand How Cancer Works
Mesothelioma Understanding your diagnosis Mesothelioma Understanding your diagnosis When you first hear that you have cancer, you may feel alone and afraid. You may be overwhelmed by the large amount of
More informationAccelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma
Accelerated hemithoracic radiation followed by extrapleural pneumonectomy for malignant pleural mesothelioma Marc de Perrot, Ronald Feld, Natasha B Leighl, Andrew Hope, Thomas K Waddell, Shaf Keshavjee,
More informationCardiac Masses and Tumors
Cardiac Masses and Tumors Question: What is the diagnosis? A. Aortic valve myxoma B. Papillary fibroelastoma C. Vegetation from Infective endocarditis D. Thrombus in transit E. None of the above Answer:
More informationCharacteristics of Malignant Pleural Mesothelioma in Women
Characteristics of Malignant Pleural Mesothelioma in Women Andrea S. Wolf, MD, MPH, William G. Richards, PhD, Tamara R. Tilleman, MD, PhD, Lucian Chirieac, MD, Shelley Hurwitz, PhD, Raphael Bueno, MD,
More information